- Full-year 2026 total revenue guidance reaffirmed at $325M to $345M with $355M in cash and cash equivalents.
- CMS finalized Q1 2027 DefenCath add-on payment at $8.32/session, up from current $2.37.
- Management distanced itself from third-party LDO commentary regarding subsequent 2027 add-on payment trajectory.
?? Positive AI Sentiment (+3.0 / 10)